Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. We are currently developing treatments for diabetes and autoimmune disorders. Our poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized and targeted drug delivery.
$8 million in seed funding since our founding in 2018. In 2020, we were accepted into the Emerging Technology Program created by the FDA to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. In 2020, StartUs Insights named Toralgen to their Top 5 Drug Delivery Startup list.
$8M
in SEED FUNDING
Our founders and executive team bring acclaimed experience and excellence in pharmaceutical research, development, and commercialization from industry-leading companies including Eli Lilly & Co., Thermalin and MBX. The combined group has more than 500 published papers, abstracts, and lectures, and has contributed to numerous patents and brand launches, with significant expertise in innovation for diabetes treatment and immunology.
Toralgen and Yale scientists have demonstrated an oral drug delivery platform that will enable improved compliance and patient experience for biotherapeutics such as those used to treat diabetes.
Inventor and Toralgen cofounder, Tarek Fahmy, conducted more than a decade of research at Fahmy Labs (Yale University), which serves as the basis for Toralgen’s development of patented platform technology.. In 2021, John Lee, Director of Development, and Gerald Rea, CEO, proudly co-authored a Nature Biomedical Engineering1 manuscript that described the results of the work from Yale.. Since then, Toralgen has focused on developing novel techniques for encapsulation of biologics and improving the bioavailability of the nanoparticle even further.
